Summary
Vertex Pharmaceuticals Inc. (VRTX) reported its annual results for the fiscal year ended December 31, 2010. The company is heavily focused on the development and commercialization of small molecule drugs, with its lead candidate, telaprevir, for Hepatitis C Virus (HCV) infection being a major point of investor interest. Vertex submitted a New Drug Application (NDA) for telaprevir in November 2010 and received priority review from the FDA, with a target completion date of May 23, 2011. The company anticipates obtaining approval and launching telaprevir in the U.S. in 2011. Beyond telaprevir, Vertex is advancing other clinical development programs, notably VX-770 for cystic fibrosis (CF), with a registration program in Phase 3. The company is strategically building its commercial capabilities in the U.S. and Canada to support potential launches. While significant investments in research and development continue, Vertex incurred substantial net losses, a pattern expected to persist until telaprevir generates substantial product revenue. Key financial highlights include total revenues of $143.4 million and a net loss of $754.6 million for 2010.
Financial Highlights
50 data points| Revenue | $143.37M |
| Cost of Revenue | $0 |
| Gross Profit | $143.37M |
| R&D Expenses | $637.42M |
| SG&A Expenses | $187.80M |
| Operating Expenses | $839.45M |
| Operating Income | -$696.08M |
| Interest Expense | $19.27M |
| Net Income | -$754.63M |
| EPS (Basic) | $-3.77 |
| EPS (Diluted) | $-3.77 |
| Shares Outstanding (Basic) | 200.40M |
| Shares Outstanding (Diluted) | 200.40M |
Key Highlights
- 1Vertex submitted an NDA for telaprevir, its lead HCV drug candidate, and received FDA priority review, with a decision expected in May 2011.
- 2The company anticipates launching telaprevir in the U.S. in mid-2011, and is building its commercial organization to support this.
- 3VX-770, a drug candidate for cystic fibrosis, is in Phase 3 clinical trials, with potential for an NDA submission in the second half of 2011.
- 4Total revenues for 2010 were $143.4 million, a 41% increase from 2009, primarily driven by collaborative revenues.
- 5The company reported a net loss of $754.6 million for 2010, an increase from $642.2 million in 2009, reflecting significant R&D investments.
- 6Vertex has a strong cash position with $1.03 billion in cash, cash equivalents, and marketable securities as of December 31, 2010.
- 7Collaborations with Janssen Pharmaceutica and Mitsubishi Tanabe Pharma are crucial for telaprevir's development and commercialization.